BDSX
Biodesix, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$26.18
−1.11%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 102.9M | 88.5M | 71.3M | 49.1M | 38.2M |
| Cost of Revenue | 18.0M | 16.7M | 15.6M | 13.0M | 14.2M |
| Gross Profit | 84.9M | 71.8M | 55.8M | 36.1M | 24.1M |
| Operating Expenses | |||||
| R&D Expense | 12.3M | 12.0M | 9.6M | 10.0M | 13.1M |
| SG&A Expense | 93.2M | 87.5M | 80.5M | 67.4M | 61.5M |
| General & Admin Expense | 24.3M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | 61.5M |
| Other Expenses | 12.0K | — | 238.0K | 44.0K | 81.0K |
| Total Operating Expenses | 105.5M | 99.5M | 90.2M | 77.4M | 74.6M |
| Cost and Expenses | 123.5M | 116.3M | 105.8M | 90.4M | 88.8M |
| Operating Income (EBIT) | (20.6M) | (27.8M) | (34.5M) | (41.3M) | (50.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 8.1M | 7.7M | 8.3M | 9.5M | 8.1M |
| Net Interest Income | (8.1M) | (7.7M) | (8.3M) | (9.5M) | (8.1M) |
| Other Non-Op Income/Expense | (7.2M) | (7.5M) | (8.4M) | (10.8M) | (14.9M) |
| Non-Operating Income (excl Interest) | (730.0K) | (217.0K) | 175.0K | 1.3M | 6.8M |
| EBT (Pre-Tax Income) | (27.8M) | (35.3M) | (42.9M) | (52.1M) | (65.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (27.8M) | (35.3M) | (42.9M) | (52.1M) | (65.4M) |
| Earnings from Cont. Ops | (27.8M) | (35.3M) | (42.9M) | (52.1M) | (65.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (27.8M) | (35.3M) | (42.9M) | (52.1M) | (65.4M) |
| Per Share | |||||
| Basic EPS | ($3.17) | ($4.67) | ($6.62) | ($12.70) | ($31.09) |
| Diluted EPS | ($3.17) | ($4.67) | ($6.62) | ($12.70) | ($31.09) |
| Revenue Per Share | $10.00 | $11.72 | $11.00 | $11.96 | $18.15 |
| Shares | |||||
| Basic Shares Outstanding | 10.3M | 7.6M | 6.5M | 4.1M | 2.1M |
| Diluted Shares Outstanding | 10.3M | 7.6M | 6.5M | 4.1M | 2.1M |
| Profitability Metrics | |||||
| EBITDA | (14.3M) | (21.9M) | (29.2M) | (37.1M) | (51.5M) |
| D&A | 5.6M | 5.6M | 5.5M | 5.5M | 5.8M |
| EBIT | (19.9M) | (27.5M) | (34.7M) | (42.6M) | (57.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026